Aflibercept Composition With Truncation Variant Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions of aflibercept face challenges in maintaining stability and efficacy due to the presence of truncation variants, which are difficult to remove and affect the quality control of the active ingredients.
Innovation Solution
A composition comprising aflibercept with a truncation variant (T100) is developed, where the content of the variant is controlled to be less than or equal to 20%, and the preparation process includes specific culture conditions and additives to minimize the variant's presence, using trypsin-cleaved peptide mass fingerprinting for analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional purification methods are used to remove truncation variants, then the purity of aflibercept is improved, but the production process complexity and cost increase
Solution Approach 1:
The patent changes the cultural parameters (temperature, pH, media composition) during cell culture to control the formation of truncation variants. By optimizing these parameters, the variant content is kept below 20%, eliminating the need for complex purification steps while maintaining product quality.
Solution Approach 2:
The patent applies preliminary action by controlling the formation of truncation variants during the cell culture process itself, rather than addressing them after production. This preventive approach ensures that the variant content remains within acceptable limits throughout the production process, avoiding the need for additional purification steps.
2Reliability
If additional purification steps are added to remove truncation variants, then the quality control is improved, but the production time and cost increase
Solution Approach 1:
The patent implements preliminary action by addressing truncation variant formation during the cell culture phase through optimized cultural conditions. This prevents the need for subsequent purification steps, thereby reducing production time while maintaining quality control through monitoring of variant content.
Solution Approach 2:
The patent employs feedback mechanisms through monitoring and analysis of truncation variant content during production. By tracking variant levels and adjusting cultural parameters accordingly, the process ensures quality control without requiring time-consuming additional purification steps.
3Manufacturing precision
If strict control of truncation variant content is implemented, then the medicinal requirements are met, but the manufacturing complexity increases
Solution Approach 1:
The patent uses parameter changes in cell culture conditions (temperature, pH, media composition) to control truncation variant content. These parameter adjustments are made during the standard production process, allowing strict content control without adding significant manufacturing complexity.
Solution Approach 2:
The patent applies self-service by utilizing the cell culture system itself to control variant formation through optimized conditions. The system naturally produces aflibercept with controlled variant content when cultural parameters are properly adjusted, eliminating the need for external purification interventions.
Data Source
AI summary
Provided is a composition comprising aflibercept and a variant thereof, wherein the variant is a truncation variant with a truncated VEGF binding portion of aflibercept, and wherein the content of the truncation variant is less than or equal to about 20% by mass percentage. Also provided is a pharmaceutical formulation comprising the composition, and a method for preparing the same. Further, provided are a method for detecting the variant and use of the variant in quality inspection or quality control of an aflibercept-containing product.